From USD 4.9 billion in 2022 to USD 8.2 billion by 2031, the worldwide in vivo toxicology market is predicted to expand at a CAGR of 5.2%. Over the projected period, North America is expected to control the market.
Rising demand for customized medicine, growing drug development activity, and strict regulatory standards for drug safety evaluation are driving constant expansion of the in vivo toxicology market. Driven by preclinical research to assess the safety and effectiveness of novel drug candidates, pharmaceutical and biotechnology firms are making growing investments in these areas, hence generating demand for in vivo toxicology services.
Vivo Toxicology Market Dynamics Market Trend Humanized animal models are being used more and more in order to provide better human medication toxicity prediction
Humanized animal models are being used in a notable trend in the in vivo toxicity industry. Comparatively to conventional animal models, these genetically engineered animals expressing human genes or proteins provide better forecasting of drug toxicity in human subjects. Humanized models help researchers to get more therapeutically relevant data during preclinical trials by better mimicking human physiology and medication reactions. The need to lower the high attrition rates in drug development and enhance the translocation of preclinical data to human outcomes fuels this movement. To improve the accuracy and efficiency of toxicity investigations, pharmaceutical corporations and contract research organizations are progressively funding these sophisticated models, thereby hastening the drug development process and lowering the expenses related with late-stage failures.
Market Agent Strict legal criteria for drug safety evaluation generate need for thorough toxicological research
The market in in vivo toxicology is mostly driven by ever strict regulations for medication safety evaluation. Before novel medication candidates may go into clinical trials or get market clearance, regulatory agencies such the FDA, EMA, and others have put strict rules for assessing their safety and effectiveness into effect. These rules demand thorough toxicological research to pinpoint any side effects and set reasonable dosages for human usage. Consequently, from lead optimization to preclinical phases, pharmaceutical and biotechnology firms are driven to do thorough in vivo toxicological investigations all through the drug development process. This driver has generated demand for enhanced animal models, specialist toxicology services, and complex testing techniques as well as for The emphasis on patient safety and the need to reduce the risk of drug-related adverse events in clinical trials and post-marketing phases underline even more the need of comprehensive toxicological evaluations, hence supporting market growth.
Restrain in the market Regulatory limits on animal experimentation and ethical issues raise questions about the possible expansion of the industry
Growing ethical concerns and legal limitations on animal experimentation constitute a major constraint in the in vivo toxicology sector. Particularly for toxicity testing of cosmetics, personal care goods, and certain forms of pharmaceuticals, public knowledge of and resistance to the use of animals in scientific research is growing. As a result, some areas have outright prohibitions on animal testing for some product categories and tougher rules and standards controlling animal care in research. For cosmetics, for example, the European Union has outlawed animal testing; some other nations have done likewise. These limits on the possible uses of in vivo toxicity investigations direct the search for substitute testing techniques and limit their possibilities. Companies in the pharmaceutical and biotechnology industries are therefore under pressure to cut their dependence on animal models and support the development of in vitro and silico substitutes. This change in favor of alternative testing techniques could help to slow down the expansion of the conventional in vivo toxicology industry in several sectors.
Rodents are the most often used animal model as they are cheap and genetically comparable to humans
Particularly mice and rats, the rodent sector dominates the animal model category of in vivo toxicity markets. Rodents and humans have physiological and genetic similarities that explain their dominance; thus, they are perfect models for investigating medication toxicity and effectiveness. Preclinical research heavily rely on rodents because of their tiny size, brief reproductive cycle, and well-defined genomes. Furthermore made possible by the availability of genetically engineered rodent strains is more focused and exact toxicological research. Further driving their extensive usage in toxicological studies is their cost-effectiveness when compared to bigger animals.
Strong pharmaceutical R&D infrastructure and strict regulatory framework help North America dominate the in vivo toxicology industry
With the United States leading the significant contribution, North America rules the worldwide in vivo toxicology market. The strong pharmaceutical and biotechnology research and development infrastructure of the area, along with a strict regulatory framework for drug safety evaluation, mostly explain the leadership of the area. Major demand for in vivo toxicology services in the area comes from the presence of university research institutes, contract research firms, and large pharmaceutical businesses. Furthermore driving market expansion are significant government support for biomedical research and medication development projects. The FDA's strict preclinical safety data requirements before allowing clinical trials or new medication approvals guarantee a constant need for thorough toxicology research. Furthermore driving the region's market leadership in in vivo toxicology are its high technical capacity, trained workforce, and emphasis on creative drug development methods.
Strong rivalry among important players including contract research organizations (CROs), pharmaceutical corporations, and university research institutes defines the in vivo toxicology industry. Offering complete toxicology services, major CROs include Charles River Laboratories, Covance (LabCorp), and Eurofins Scientific predominate on the market. To stay in their markets, these businesses keep investing in broadening their service offerings, improving technology capacity, and strategic alliances. Furthermore important in the competitive scene are pharmaceutical behemoths with in-house toxicology departments. Mergers and acquisitions are helping businesses strive to expand their service offerings and geographical presence by means of rising consolidation of the market. To carve out their market share, furthermore, new firms are concentrating on specialist areas such sophisticated toxicity endpoints or specialized animal models. The increasing need for integrated drug development services fuels businesses to provide end-to-end solutions from early-stage research to clinical trials, therefore intensifying the competitiveness.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global In Vivo Toxicology Market (2018 – 2022)
3.2. Global In Vivo Toxicology Market (2023 – 2031)
3.2.1. Market Segment By Animal Model (2023 – 2031)
3.2.2. Market Segment By Toxicity Endpoints (2023 – 2031)
3.2.3. Market Segment By Testing Type (2023 – 2031)
3.2.4. Market Segment By End-user (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Increasing adoption of humanized animal models for improved predictability of drug toxicity in humans
4.1.2. Growing focus on precision medicine and personalized toxicology
4.1.3. Advancements in imaging technologies for non-invasive toxicity assessment
4.2. Market Drivers
4.2.1. Stringent regulatory requirements for drug safety assessment driving demand for comprehensive toxicology studies
4.2.2. Rising R&D investments in pharmaceutical and biotechnology sectors
4.2.3. Increasing prevalence of chronic diseases spurring drug development activities
4.3. Market Restraints
4.3.1. Ethical concerns and regulatory restrictions on animal testing limiting market growth potential
4.3.2. High costs associated with in vivo toxicology studies
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY ANIMAL MODEL (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Rodents
5.2. Non-rodents
6. BY TOXICITY ENDPOINTS
6.1. Acute
6.2. Sub-acute
6.3. Sub-chronic
6.4. Chronic
7. BY TESTING TYPE
7.1. Systemic
7.2. Dermal
7.3. Ocular
7.4. Others
8. BY END-USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Academic & Research Institutions
8.3. Contract Research Organizations
9. GEOGRAPHY
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
10. COMPETITIVE LANDSCAPE
10.1. Key Developments
10.2. Company Market Share Analysis
10.3. Product Benchmarking
11. SWOT ANALYSIS
12. COMPANY PROFILES
12.1. Charles River Laboratories
12.2. Covance (LabCorp)
12.3. Eurofins Scientific
12.4. Envigo
12.5. Thermo Fisher Scientific
12.6. Taconic Biosciences
12.7. Jackson Laboratory
12.8. Inotiv
12.9. Sinclair Research
12.10. Janvier Labs
12.11. Biocytogen
12.12. GenOway (*LIST NOT EXHAUSTIVE)
13. MARKET OPPORTUNITIES
By Animal Model:
Rodents
Non-rodents
By Toxicity Endpoints:
Acute
Sub-acute
Sub-chronic
Chronic
By Testing Type:
Systemic
Dermal
Ocular
Others
By End-user:
Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Contract Research Organizations
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
